Navigation Links
Patient's Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation
Date:6/18/2008

Case is first to show safety and effectiveness of using cloned cells alone

to kill tumors

SEATTLE, June 18 /PRNewswire/ -- Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.

Yee and colleagues removed CD4+ T cells, a type of white blood cell, from a 52-year-old man whose Stage 4 melanoma had spread to a groin lymph node and to a lung. T cells specific to targeting the melanoma were then expanded vastly in the laboratory using modifications to existing methods. The lab-grown cells were then infused into the patient with no additional pre- or post-conditioning therapies, such as growth-factor or cytokine treatment. Two months later, PET and CT scans revealed no tumors. The patient remained disease free two years later, when he was last checked.

"We were surprised by the anti-tumor effect of these CD4 T cells and its duration of response," Yee said. "For this patient we were successful, but we would need to confirm the effectiveness of therapy in a larger study."

Yee cautioned that these results, presented in the journal's "Brief Report" section, represent only one patient with a specific type of immune system whose tumor cells expressed a specific antigen. More studies are needed to confirm the effectiveness of the experimental T cell therapy. If proven successful in more patients, Yee predicted this therapy could be used for the 25 percent of all late-stage melanoma patients who have the same immune-system type and tumor antigen.

Using a patient's own immune system to combat cancer, called immunotherapy, is a growing area of research that aims to develop
'/>"/>

SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Sysmex America, Inc., ... information systems technology, will feature an exhibit booth during ... Meeting and Clinical Lab Expo in ... "We are extremely excited to exhibit ... to interact with our customers and continue the dialogue ...
(Date:7/29/2014)... , July 29, 2014 Apex Medical Corporation (Apex, ... Pressure Area Care sectors, announces that it is appealing the ... in Germany that found the ... notes that it has initiated invalidity challenges against various ResMed ... in counterattacking against trivial and junk patents. ...
(Date:7/29/2014)... July 29, 2014  Drug development for hepatitis ... incidence rates and the intense need for curative ... Change is underway as the market moves away ... effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first of ...
Breaking Medicine Technology:New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Apex Continues Fighting Against Patents to Free Up Competition 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
(Date:7/29/2014)... July 29, 2014 – Silverado, a provider of memory ... that it is a Bronze winner in the 35th Annual ... Through a Child's Eye and Silverado Resident Visits ... a Child's Eye , seven-year-old Mia Sandoval shares her experience ... a memory care community in Los Angeles. The feel-good video ...
(Date:7/29/2014)... 29, 2014 According to a new ... leading global authority in medical device market research, the ... to over $8 billion by 2018. This growth ... the transcatheter heart valve market, which is comprised of ... transcatheter mitral valve repair (TMVR) segments. , There are ...
(Date:7/29/2014)... 29, 2014 According to the New ... the recreational and the medicinal sectors is mirroring the ... becomes more accepted in mainstream culture, many are turning ... the traditional and more dangerous forms of smoking the ... quite the trend in legalized states such as Colorado ...
(Date:7/29/2014)... 2014Today the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and ... to improve access to essential pain medications for people ... ACS, Treat the Pain initiative, this new partnership will ... HIV/AIDS services throughout the country. , Swaziland has ... than 26 percent of adults ages 15-49 infected. Many ...
(Date:7/29/2014)... 29, 2014 Officials with OZ Naturals ... in the UK in September. , Craig Romero, CEO of ... Sept. 7 on Amazon.co.uk. , “Demand for OZ Naturals products ... are truly looking forward to serving the European market,” Romero ... bestselling Vitamin C serum and hyaluronic acid ...
Breaking Medicine News(10 mins):Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:Marijuana Edibles Sales Show Growth in Market 2Health News:New partnership to improve access to essential pain medications for people living with HIV 2Health News:OZ Naturals to Launch Its Products in the UK 2
... planned strategic growth that ... Lansing and Michigan, LANSING, Mich., Oct. 8 In ... Grand River, accommodate up to 500 new jobs for,Lansing and ... subsidiary Accident Fund Insurance Company of America announced,today it will ...
... MURRYSVILLE, Pa., Oct. 8 Dixtal Medical, Inc.,and ... that Dixtal Medical,has acquired the Novametrix pulse oximetry ... will be marketed under the,Dixtal/Novametrix brand pursuant to ... Novametrix, founded in 1978 and acquired,by Respironics in ...
... mean more estrogen, bringing higher odds for the illness, researchers ... and shape of a woman,s hips may affect her daughter,s ... The study of 6,370 Finnish women found that breast cancer ... mothers with relatively wide hips, and nearly seven times higher ...
... Brothers is proud to be the,leading supplier of Official ... extends over 90 years. The embroidered badges and awards,produced ... substances. As a global manufacturer, Lion Brothers maintains ... substances in any of its,manufacturing processes. Lion tests materials ...
... Bristol-Myers Squibb Company,(NYSE: BMY ) will announce ... 25. During a conference call on October 25 at ... executives will,address inquiries from investors and analysts. Investors ... a live,webcast of the call at http://www.bms.com/ir ...
... or useless, the appendix now appears to have a reason ... bacteria living in the human gut. , Drawing upon a ... postulate that the beneficial bacteria in the appendix that aid ... evacuates the intestines and emerge afterwards to repopulate the gut. ...
Cached Medicine News:Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 2Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 3Health News:Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics 2Health News:Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics 3Health News:Woman's Hips Might Indicate Daughter's Breast Cancer Risk 2Health News:Appendix isn't useless at all: It's a safe house for bacteria 2Health News:Appendix isn't useless at all: It's a safe house for bacteria 3
... Drug Interaction Principles is the number one ... , An understanding of drug interactions has ... Since publication of the first edition of ... pharmacopoeia - coupled with prolonged human life ...
... drug information reference that integrates ... patient care guidelines., The sixth ... 4,700 drugs, including the latest ... indications, dosages, side effects and ...
Updated for 2006 with more than 800 complete drug entries, this mobile reference provides instant access to all the drug information nurses need in day-to-day practice....
... ACM-8 loads and unloads two centrifuges with ... via Cap Recognition the tube type is ... batches of three 5 position racks into ... single centrifuge ACM can be offered for ...
Medicine Products: